GERON CORP Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
GERON CORP (GERN) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $4.87 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-05
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.87M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.17M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.45M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.74M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $4.87M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.17M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $5.45M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.74M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $6.01M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $6.27M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $6.53M 10-K · filed 2025-02-27 |
| 2024-09-30 | $258.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $330.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $458.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $605.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $408.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $483.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $556.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $628.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |